CN112316282A - Drug-coated balloon dilatation catheter for intracranial blood vessels - Google Patents
Drug-coated balloon dilatation catheter for intracranial blood vessels Download PDFInfo
- Publication number
- CN112316282A CN112316282A CN202011338339.4A CN202011338339A CN112316282A CN 112316282 A CN112316282 A CN 112316282A CN 202011338339 A CN202011338339 A CN 202011338339A CN 112316282 A CN112316282 A CN 112316282A
- Authority
- CN
- China
- Prior art keywords
- drug
- balloon
- coated
- layer
- saccule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 108
- 229940079593 drug Drugs 0.000 title claims abstract description 86
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 25
- 238000007917 intracranial administration Methods 0.000 title claims abstract description 20
- 239000011248 coating agent Substances 0.000 claims abstract description 44
- 238000000576 coating method Methods 0.000 claims abstract description 44
- 210000005077 saccule Anatomy 0.000 claims abstract description 32
- 230000003902 lesion Effects 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 7
- 230000008569 process Effects 0.000 claims abstract description 7
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 4
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 150000004579 taxol derivatives Chemical class 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 abstract description 4
- 208000037803 restenosis Diseases 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- 239000011247 coating layer Substances 0.000 abstract description 2
- 239000010410 layer Substances 0.000 description 30
- 208000032382 Ischaemic stroke Diseases 0.000 description 8
- 230000002490 cerebral effect Effects 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 4
- 210000001627 cerebral artery Anatomy 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
- 206010062325 Congenital arterial malformation Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001094 effect on targets Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940127022 high-dose drug Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M29/00—Dilators with or without means for introducing media, e.g. remedies
- A61M29/02—Dilators made of swellable material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M2025/0008—Catheters; Hollow probes having visible markings on its surface, i.e. visible to the naked eye, for any purpose, e.g. insertion depth markers, rotational markers or identification of type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
- A61M2025/0039—Multi-lumen catheters with stationary elements characterized by lumina being arranged coaxially
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
- A61M2025/0046—Coatings for improving slidability
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The invention discloses a drug-coated balloon dilatation catheter for intracranial blood vessels, belonging to the field of medical instruments. The drug coating balloon dilatation catheter consists of a tip, a developing ring, a drug coating, a balloon, an inner tube, an outer tube and a handle, wherein the surface of the outer tube is coated with a hydrophilic coating; the front end of the inner tube is provided with a tip; a saccule is fixed behind the tip, and a developing ring is arranged on an inner tube in the saccule; the balloon is connected with the outer tube, the inner tube penetrates through the balloon and the outer tube and is connected with the operation knob, and the outer tube is connected with the handle; the inner surface of the saccule outside the inner tube is coated with a drug coating layer which is coated on the periphery of the inner tube. The intracranial drug coating balloon dilatation catheter is loaded with the anti-cell proliferation drug, and the drug is firmly locked on the balloon by using a special balloon curling mode, so that a small amount of effective drug is lost in the catheter conveying process, and a large amount of effective drug is conveyed to the vessel wall when a lesion part is expanded, and the occurrence of restenosis is reduced. Meanwhile, the intervention is not implanted, the stimulation is reduced, and the safety is improved.
Description
Technical Field
The invention belongs to the field of medical instruments, and particularly relates to a drug-coated balloon dilatation catheter for intracranial blood vessels.
Background
With the gradual improvement of living standard and life of people and the gradual rise of working pressure, the phenomenon of cerebral apoplexy is more and more common, and has the trend of youthfulness, which brings inconvenience to the daily life of people. Cerebral apoplexy is divided into cerebral arterial thrombosis and hemorrhagic stroke. The hemorrhagic stroke is mainly caused by cerebral vascular rupture, and is commonly seen in patients with hypertension, smoking history, aneurysm and cerebral artery malformation. Ischemic stroke is a chronic disease, and is caused by insufficient blood supply due to the stenosis of cerebral arteries or the blood embolism of cerebral arteries. Of all stroke patients, approximately 70% and above are caused by cerebral vascular ischemia, and it can be said that ischemic stroke has gradually become one of the biggest killers of human health.
Most of the early treatment means of ischemic stroke are medicines, and patients are treated in stages through thrombolytic drugs, defibrination drugs, anticoagulant drugs, platelet aggregation resistant drugs, nerve protection drugs and statins, so that a certain effect is achieved. However, the drug therapy is not targeted drug delivery at first, and after entering a human body, high-dose drugs have little effect on target blood vessels, so that the bioavailability is low, and the drug therapy does not conform to the current popular targeted engineering. In recent years, the cerebral ischemic stroke treatment is divided into Acute Ischemic Stroke (AIS) and intracranial atherosclerosis (ICAD), and in AIS treatment, in order to dredge the cerebral vessels blocked by thrombus as soon as possible, a thrombus suction system or a thrombus taking support is generally adopted to take out the thrombus. ICAD, however, differs from AIS in its pathogenesis, and is a chronic disease affecting large and medium-sized elasticity and muscular arteries of the whole body characterized by progressive lipid deposition, fibrous tissue proliferation and inflammatory cell infiltration, and has prominent manifestations in the cerebral blood supply arterial system. On ICAD interventional devices, there are naked balloons and naked stents on the market at present, and although brain interventional and implantation devices have taken on the stage, over several years of clinical application and summarizing the implantation interventional products in the coronary field, the treatment effect of the naked balloons and the naked stents on stenosis of cerebral vessels or cerebral artery thromboembolism is not obvious or even inferior to drug treatment. Therefore, there is a lack of a practical instrument for ICAD.
The concept of drug-coated balloon dilatation catheters has been proposed for some time and the current fields of application include coronary, peripheral, arteriovenous fistulas and the like, have shown good safety and efficacy. The medicine balloon is an interventional instrument, and is characterized in that the medicine for resisting cell proliferation is given on the balloon in a certain mode, in the operation, the medicine is directly acted on a target lesion blood vessel in a balloon expansion mode, and finally the medicine is absorbed by the target lesion blood vessel, so that the cell proliferation is prevented, and the blood vessel stenosis is prevented.
Although the drug balloon is a very efficient target drug delivery device, since the existing technology physically attaches the drug on the balloon, the current technical bottleneck is focused on how to deliver the drug to the lesion more effectively without being washed away by blood during the delivery process. Thereby leading the target blood vessel to obtain more efficient drug treatment and achieving more effective treatment effect.
Disclosure of Invention
The invention aims to provide a drug-coated balloon dilatation catheter for intracranial blood vessels, which is characterized by consisting of a tip, a developing ring, a drug coating, a balloon, an inner tube, an outer tube and a handle, wherein the surface of the outer tube is coated with a hydrophilic coating; the front end of the inner tube 5 is provided with a tip 1; a saccule 4 is fixed behind the tip 1, and a developing ring 2 is arranged on an inner tube 5 in the saccule 4; the right end of the balloon 4 is connected with the outer tube 6 and is connected with an operation knob; the inner tube 5 passes through the balloon 4 and the outer tube 6, and the outer tube 6 is connected with the handle 7; the inner surface of the balloon 4 outside the inner tube 5 is coated with a drug coating 3 around the inner tube 5.
The saccule is divided into more than or equal to 3 petals and is wrapped on the periphery of the inner tube 5 to form a three-leaf fin saccule; spraying the liquid medicine 8 on the pits of the three-blade fins by using a medicine coating device 9 to form a medicine coating 3; the concave pit of the balloon valve can receive more effective medicines; the inner layer of the drug coating 3, which is in contact with the surface of the balloon, is a crystallization layer and is called an 'ice layer', the outer layer is in one or more layers of micro-particle states and is called a 'snow layer', and the double-layer or multi-layer structure has the advantages that the dense 'snow layer' can protect effective drugs of the 'ice layer' to directly reach a lesion position and directly act on a blood vessel wall; and finally, rolling the saccule coated with the ice layer and the snow layer by adopting saccule curling equipment, and attaching the rolled saccule to the inner tube, wherein under the structure, more effective medicines are protected in the valve of the saccule so as to achieve the aim of reducing the medicine loss in the conveying process, and the medicine coating saccule dilatation catheter is obtained.
The drug coating balloon dilatation catheter is of a rapid exchange Rx structure or is of a coaxial double-cavity OTW structure; wherein the length range of the balloon effective area is 5 mm-40 mm, and the diameter range is 1.0 mm-4.5 mm;
the whole effective length range of the dilatation catheter is 1350 mm-1450 mm.
The drug coating covers the effective area of the balloon and is composed of drugs capable of resisting cell proliferation, and the drugs include one or a combination of more of paclitaxel, paclitaxel derivatives, rapamycin derivatives and arsenic trioxide.
The drug coating of the drug coating balloon is of a double-layer or multi-layer structure, and the mass ratio of the effective drug at the innermost layer to the effective drug at the outer layer of the drug coating is 1: 0.01-1: 1.
The hydrophilic coating is coated on the surface of the outer tube, and the hydrophilic coating is arranged on partial area of the outer tube, so that the catheter is smoother after entering the blood vessel and can pass through the blood vessel with intracranial tortuous lesion more easily.
Compared with the naked saccule and the naked stent which are on the market in the intracranial, the intracranial drug coating saccule dilatation catheter carries the anti-cell proliferation drug and uses a special saccule curling mode to firmly lock the drug on the saccule, so that a small amount of effective drug is lost in the catheter conveying process, and a large amount of effective drug is conveyed to the vessel wall when a lesion part is expanded, and the occurrence of restenosis is reduced. Meanwhile, the intervention is not implanted, the stimulation is reduced, and the safety is improved.
Drawings
Fig. 1 is a structural schematic diagram of a drug-coated balloon dilatation catheter.
Fig. 2 is a schematic structural view of a drug-coated balloon being segmented into 3 lobes.
FIG. 3 is a schematic diagram of a drug coating apparatus spraying a drug solution onto the dimples of a tri-lobe fin.
Fig. 4 is a schematic cross-sectional view of a crimped balloon.
Detailed Description
The invention provides a drug-coated balloon dilatation catheter for intracranial blood vessels, which is described below by combining the accompanying drawings.
A schematic structural diagram of a drug-coated balloon dilatation catheter as shown in figure 1. The balloon dilatation catheter for intracranial drug coating is shown in the figure, which consists of a tip, a developing ring, a drug coating, a balloon, an inner tube, an outer tube and a handle, wherein the surface of the outer tube 6 is coated with a hydrophilic coating; the front end of the inner tube 5 is provided with a tip 1; a saccule 4 is fixed behind the tip 1, and a developing ring 2 is arranged on an inner tube 5 in the saccule 4; the right end of the balloon 4 is connected with an outer tube 6, and an inner tube 5 penetrates through the balloon 4 and the outer tube 6 and is connected with an operation knob; the outer tube 6 is connected with a handle 7; the inner surface of the balloon 4 outside the inner tube 5 is coated with a drug coating 3 around the inner tube 5.
The drug-coated balloon is segmented into 3-segment structure as shown in fig. 2. The saccule is divided into more than or equal to 3 petals and is wrapped on the periphery of the inner tube 5 to form a three-leaf fin saccule; spraying a liquid medicine 8 on the pits of the three-blade fin by using a medicine coating device 9 to form a medicine coating 3 (shown in figure 3); the concave pit of the balloon valve can receive more effective medicines; the inner layer of the drug coating layer, which is in contact with the surface of the balloon, is a crystallization layer and is called an 'ice layer', the outer layer is in one or more layers of micro-particle states and is called a 'snow layer', and the double-layer or multi-layer structure has the advantages that the dense 'snow layer' can protect effective drugs of the 'ice layer' to directly reach a lesion position and directly act on a blood vessel wall; and finally, the saccule coated with the ice layer and the snow layer is rolled up by a saccule curling device and is attached to the inner tube (as shown in figure 4), and under the structure, more effective medicines are protected in the valve of the saccule so as to achieve the purpose of reducing the medicine loss in the conveying process, namely the medicine coating saccule dilatation catheter is obtained.
The drug coating balloon dilatation catheter is of a rapid exchange Rx structure or is of a coaxial double-cavity OTW structure; wherein the length range of the balloon effective area is 5 mm-40 mm, and the diameter range is 1.0 mm-4.5 mm; the whole effective length range of the dilatation catheter is 1350 mm-1450 mm. The effective area of the balloon covered by the drug coating is composed of drugs capable of resisting cell proliferation, and the drugs comprise one or more of paclitaxel, paclitaxel derivatives, rapamycin derivatives and arsenic trioxide. The mass ratio of the effective medicine at the innermost layer of the medicine coating to the effective medicine at the outer layer is 1: 0.01-1: 1.
And the hydrophilic coating is coated on the surface of the outer tube, namely the hydrophilic coating is arranged on part of the area of the outer tube, so that the catheter is smoother after entering the blood vessel and can more easily pass through the blood vessel with intracranial tortuous lesion.
The intracranial drug coating balloon dilatation catheter is loaded with the anti-cell proliferation drug, and the drug is firmly locked on the balloon by using a special balloon curling mode, so that a small amount of effective drug is lost in the catheter conveying process, and a large amount of effective drug is conveyed to the vessel wall when a lesion part is expanded, and the occurrence of restenosis is reduced. Meanwhile, the intervention is not implanted, the stimulation is reduced, and the safety is improved.
Claims (6)
1. A drug-coated balloon dilatation catheter for intracranial blood vessels, which is characterized by consisting of a tip, a developing ring, a drug coating, a balloon, an inner tube, an outer tube and a handle, wherein the surface of the outer tube is coated with a hydrophilic coating; the front end of the inner tube (5) is provided with a tip (1); a saccule (4) is fixed behind the tip (1), and a developing ring (2) is arranged on an inner tube (5) in the saccule (4); the right end of the balloon (4) is connected with the outer tube (6), and the inner tube (5) penetrates through the balloon (4) and the outer tube (6) and is connected with the operation knob; the outer tube (6) is connected with the handle (7), and the inner surface of the saccule (4) outside the inner tube (5) is coated with the drug coating (3) which is wrapped on the periphery of the inner tube (5).
2. The drug-coated balloon dilatation catheter for intracranial blood vessels as claimed in claim 1, wherein the balloon is segmented into 3 or more segments and wrapped around the inner tube (5) forming a tri-lobed-fin balloon; spraying a liquid medicine (8) on the pits of the three-blade fins by using a medicine coating device (9) to form a medicine coating (3); the concave pit of the balloon valve can receive more effective medicines; the inner layer of the drug coating (3) in contact with the surface of the balloon is a crystallization layer and is called an 'ice layer', the outer layer is in one or more layers of micro-particle states and is called a 'snow layer', and the double-layer or multi-layer structure has the advantages that the effective drugs of the 'ice layer' can be protected by the compact 'snow layer' to directly reach the lesion site and directly act on the blood vessel wall; and finally, rolling the saccule coated with the ice layer and the snow layer by adopting saccule curling equipment, and attaching the rolled saccule to the inner tube, wherein under the structure, more effective medicines are protected in the valve of the saccule so as to achieve the aim of reducing the medicine loss in the conveying process, and the medicine coating saccule dilatation catheter is obtained.
3. The drug-coated balloon dilatation catheter for intracranial blood vessels according to claim 1 wherein the drug-coated balloon dilatation catheter is a fast-exchange Rx structure or a coaxial dual-lumen OTW structure; wherein the length range of the balloon effective area is 5 mm-40 mm, and the diameter range is 1.0 mm-4.5 mm; the whole effective length range of the dilatation catheter is 1350 mm-1450 mm.
4. The drug-coated balloon dilatation catheter for intracranial vessels according to claim 1 wherein the drug-coated effective area covering the balloon consists of a drug capable of resisting cell proliferation including one or a combination of paclitaxel, paclitaxel derivatives, rapamycin derivatives and arsenic trioxide.
5. The drug-coated balloon dilatation catheter for intracranial blood vessels as claimed in claim 4, wherein the drug coating of the drug-coated balloon is of a double-layer or multi-layer structure, and the mass ratio of the effective drug at the innermost layer to the effective drug at the outer layer of the drug coating is 1: 0.01-1: 1.
6. The drug-coated balloon dilatation catheter for intracranial blood vessels as claimed in claim 1, wherein the hydrophilic coating on the outer tube surface is a hydrophilic coating on a partial area of the outer tube, so that the catheter is smoother after entering the blood vessels and easier to pass through the blood vessels with intracranial tortuous lesions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011338339.4A CN112316282A (en) | 2020-11-25 | 2020-11-25 | Drug-coated balloon dilatation catheter for intracranial blood vessels |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011338339.4A CN112316282A (en) | 2020-11-25 | 2020-11-25 | Drug-coated balloon dilatation catheter for intracranial blood vessels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112316282A true CN112316282A (en) | 2021-02-05 |
Family
ID=74307929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011338339.4A Pending CN112316282A (en) | 2020-11-25 | 2020-11-25 | Drug-coated balloon dilatation catheter for intracranial blood vessels |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112316282A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115969467A (en) * | 2022-09-30 | 2023-04-18 | 北京管桥医疗科技有限公司 | Pulmonary artery thrombus removal system and use method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102755690A (en) * | 2012-07-19 | 2012-10-31 | 浙江海圣医疗器械有限公司 | Implementation method of hydrophilic coating of ultra-soft SV |
| CN106075703A (en) * | 2016-07-27 | 2016-11-09 | 杭州唯强医疗科技有限公司 | Medicine carrying sacculus and the manufacture method of medicine carrying sacculus thereof |
| US20180304052A1 (en) * | 2014-11-03 | 2018-10-25 | Cagent Vascular, Llc | Medical balloon |
| CN108744233A (en) * | 2018-06-28 | 2018-11-06 | 山东吉威医疗制品有限公司 | A kind of medicine balloon dilating catheter and its technique |
| CN214260325U (en) * | 2020-11-25 | 2021-09-24 | 北京管桥医疗科技有限公司 | Drug-coated balloon dilatation catheter for intracranial blood vessels |
-
2020
- 2020-11-25 CN CN202011338339.4A patent/CN112316282A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102755690A (en) * | 2012-07-19 | 2012-10-31 | 浙江海圣医疗器械有限公司 | Implementation method of hydrophilic coating of ultra-soft SV |
| US20180304052A1 (en) * | 2014-11-03 | 2018-10-25 | Cagent Vascular, Llc | Medical balloon |
| CN106075703A (en) * | 2016-07-27 | 2016-11-09 | 杭州唯强医疗科技有限公司 | Medicine carrying sacculus and the manufacture method of medicine carrying sacculus thereof |
| CN108744233A (en) * | 2018-06-28 | 2018-11-06 | 山东吉威医疗制品有限公司 | A kind of medicine balloon dilating catheter and its technique |
| CN214260325U (en) * | 2020-11-25 | 2021-09-24 | 北京管桥医疗科技有限公司 | Drug-coated balloon dilatation catheter for intracranial blood vessels |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115969467A (en) * | 2022-09-30 | 2023-04-18 | 北京管桥医疗科技有限公司 | Pulmonary artery thrombus removal system and use method |
| CN115969467B (en) * | 2022-09-30 | 2024-01-19 | 北京管桥医疗科技有限公司 | Pulmonary artery thrombus removal system and application method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014207862B2 (en) | Apparatus and method for delivering intraluminal therapy | |
| WO2015070814A1 (en) | Drug-eluting balloon and preparation method therefor | |
| US9468746B2 (en) | Systems and methods for local bioactive material delivery | |
| CN211584835U (en) | Medicine balloon catheter | |
| CN111568500A (en) | Blood vessel recanalization system for cardiovascular stenosis lesion | |
| CN110548212B (en) | Double-balloon catheter with self-perfusion function | |
| US20090287166A1 (en) | Integrated device for ischemic treatment | |
| EP2185233B1 (en) | Anti-restenosis drug covered and eluting balloons for valvuloplasty of aortic valve stenosis for the prevention of restenosis | |
| WO2009064806A1 (en) | Method and agent for in-situ stabilization of vascular tissue | |
| CN214260325U (en) | Drug-coated balloon dilatation catheter for intracranial blood vessels | |
| CN114082085A (en) | Pre-expanding type double-layer drug perfusion balloon dilatation catheter | |
| JP2022547024A (en) | Methods and devices for delivery of cell therapy | |
| EP3930820A1 (en) | Apparatus and methods for restoring tissue | |
| CN112316282A (en) | Drug-coated balloon dilatation catheter for intracranial blood vessels | |
| CN112401975A (en) | Ultrasonic balloon with function of directionally breaking calcified plaque in cavity and preparation method thereof | |
| CN116474245A (en) | Balloon catheter | |
| US20120283624A1 (en) | Drug Eluting Device and Method of Use Thereof | |
| CN102974026A (en) | Arsenic trioxide controllable-releasing balloon and preparing method thereof | |
| CN207821956U (en) | A kind of expandable stent system | |
| CN107995869B (en) | Surface liquefied drug coating sacculus | |
| CN110430915A (en) | Method and apparatus for delivering cell therapy | |
| WO2021060494A1 (en) | Treatment device and treatment method | |
| CN205054514U (en) | Blood vessel bracket | |
| EP2682153B1 (en) | Device for treatment of a blood vessel | |
| GB2370779A (en) | Endoluminal centring catheter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |